Wiley
Wiley.com
Print this page Share

Sepsis: New Insights, New Therapies, Novartis Foundation Symposium, No. 280

ISBN: 978-0-470-02798-1
302 pages
March 2007
Sepsis: New Insights, New Therapies, Novartis Foundation Symposium, No. 280 (0470027983) cover image
Sepsis: New Insights, New Therapies brings together contributions from an international group of experts in diverse fields to consider how the various pathways implicated in early and late sepsis interact, with a particular emphasis on novel concepts and potential new therapeutic approaches. Topics covered include adaptive immunity, inflammation, neuroendocrinology, bioenergetics and metabolism. Several chapters in the latter half of the book are particularly concerned with treatment strategies involving modulation of the neuroendocrine response.
  • Addresses the frequent, but under-recognised condition of sepsis and discusses new ways to prevent and treat it
  • Describes numerous pharmacological approaches to therapy for early and late sepsis
  • Includes detailed discussion of the various physiological systems implicated in sepsis
  • Presents an international perspective, featuring contributions from experts from laboratories worldwide involved in the study of sepsis

Sepsis: New Insights, New Therapies is an invaluable resource for all critical care physicians and researchers. It is also informative reading for immunologists, endocrinologists, neuroendocrinologists, physiologists, and pharmacologists.

See More
Symposim on Sepsis: new insights, new therapies, held at the Novartis Foundation, London, 14-16 February 2006.

Editors: Derek J. Cahdwick (Organizer) and Jamie Goode.

This Symposim was based on a proposal made by Mitchell Fink and Mervyn Singer.

Chair’s introduction (Mitchell P. Fink).

Discussion.

Strategies to modulate cellular energetic metabolism during sepsis (Alessandro Protti and Mervyn Singer).

Discussion.

Immunostimulation is a rational therapeutic strategy in sepsis (Jérôme Pugin).

Discussion.

Blockade of apoptosis as a rational therapeutic strategy for the treatment of sepsis (Alfred Ayala, Doreen E. Wesche-Soldato, Mario Perl, Joanne L. Lomas-Neira, Ryan Swan and Chun-Shiang Chung).

Discussion.

Modulating neutrophil apoptosis (John C. Marshall, Zeenat Malam and Songhui Jia).

Discussion.

HMGB1 as a potential therapeutic target(Haichao Wang, Wei Li, Richard Goldstein, Kevin J. Traceyand Andrew E. Sama).

Discussion.

Poly (ADP-ribose) polymerase activation and circulatory shock (Csaba Szabó).

Discussion.

Choosing the right substrate (Xavier Leverve, Cécile Batandier and Eric Fontaine).

Discussion.

Inhibiting glycogen synthase kinase 3β in sepsis (Laura Dugo, Marika Collin, David A. Allen, Nimesh S.A. Patel, Inge Bauer, Eero M. A. Mervaala, Marjut Louhelainen, Simon J. Foster, Muhammad M. Yaqoob and Christoph Thiemermann).

Discussion.

Ethyl pyruvate: a novel treatment for sepsis (Mitchell P. Fink).

Discussion.

General discussion I.

Cytoprotective and anti-inflammatory actions of carbon monoxide in organ injury and sepsis models(Stefan W. Ryter and Augustine M. K. Choi).

Discussion.

The hypothalamic pituitary adrenal axis in sepsis (Andrea Polito, Jérôme Aboab andDjillali Annane).

Discussion.

Modulating the endocrine response in sepsis: insulin and blood glucose control (Ilse Vanhorebeek, Lies Langouche and Greet Van den Berghe).

Discussion.

The neuronal strategy for inflammation(Luis Ulloaand Ping Wang).

Discussion.

Beta-blockade in burns (C. T. Pereira, M. G. Jeschke and D. N. Herndon).

Discussion.

System interactions (Mervyn Singer).

Discussion.

Protecting the permeability pore and mitochondrial biogenesis (C. A. Piantadosi, M. S. Carraway, D. W. Haden and H. B. Suliman).

Discussion.

Contributor Index.

Subject index.

See More
The Novartis Foundation is an international scientific and educational charity which promotes the study and general knowledge of science and in particular encourages international co-operation in scientific research.
Chairman: Mitchell Fink
See More
Buy Both and Save 25%!
+

Sepsis: New Insights, New Therapies, Novartis Foundation Symposium, No. 280 (US $212.00)

-and- Innate Immunity to Pulmonary Infection, No. 279 (US $212.00)

Total List Price: US $424.00
Discounted Price: US $318.00 (Save: US $106.00)

Buy Both
Cannot be combined with any other offers. Learn more.
Back to Top